SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 31% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: radiationcell carcinomaipilimumabmetastaticchronic
  Phrases that lowered it: participantsevaluate thebased ontopical20
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 27.8% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: 8.6% (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: not given (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 88.4% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 15691 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease NCT02843165 · started 2016 · scored riskier than 92% of active trials completed
• Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) NCT02231749 · started 2014 · scored riskier than 36% of active trials completed
• Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer NCT01943188 · started 2014 · scored riskier than 34% of active trials terminated
• SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients NCT03065179 · started 2017 · scored riskier than 85% of active trials completed
• High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer NCT01896271 · started 2013 · scored riskier than 92% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.